Revance Therapeutic (RVNC) PT Lowered to $25 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Revance Therapeutic (RVNC) PT Lowered to $26 at Mizuho Securities
October 18, 2021 6:34 AM EDTMizuho Securities analyst Difei Yang lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $26.00 (from $36.00) while maintaining a Buy rating.... More
Revance Therapeutic (RVNC) PT Lowered to $18 at H.C. Wainwright
October 18, 2021 6:33 AM EDTH.C. Wainwright analyst Douglas Tsao lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $18.00 (from $26.00) while maintaining a Buy rating.... More
Revance Therapeutics (RVNC) Announces FDA is Unable to Approve DaxibotulinumtoxinA; Management Plans to Request Type A Meeting
October 18, 2021 5:17 AM EDT(Updated - October 18, 2021 6:40 AM EDT)
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has issued a Complete Response Letter, or CRL, regarding the Biologics... More
